Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Adenocarcinoma

Adenocarcinoma of Lung

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Adenocarcinoma

Gastrointestinal Agents

All Drugs and Chemicals

Pancrelipase

Pancreatin

This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed.

at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.

This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed.

at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.

This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed.

at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.

their will be no intervention in any of the groups, the study is retrospective

The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating transcription, and inducing apoptosis.

Various studies proved p63 as a marker of basal cells in normal salivary glands, breast, prostate, respiratory and squamous epithelia, and of tumor cells from various malignancies. Still, p63 has been the subject of relatively few studies in lung adenocarcinoma, and breast carcinoma, and no study has described the correlation of p63 with pancreatic ductal adenocarcinoma.

In the current study, we aim to evaluate the prognostic value of the expression of p63 in the lung adenocarcinoma, breast adenocarcinoma, and pancreatic ductal adenocarcinoma. We will achieve this aim by collecting clinical data retrospectively from the patients' medical records as well as assessing the histological sections and performing immunohistochemical staining for p63.

Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas

Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas

if the patient is alive or dead 5 years following the treatment

the recurrence of the disease within 5 years from the treatment

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas	NCT01942629	Lung Adenocarci... Breast Adenocar... Pancreatic Duct...	their will be n...	18 Years - 75 Years	Rambam Health Care Campus
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas	NCT01942629	Lung Adenocarci... Breast Adenocar... Pancreatic Duct...	their will be n...	18 Years - 75 Years	Rambam Health Care Campus
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas	NCT01942629	Lung Adenocarci... Breast Adenocar... Pancreatic Duct...	their will be n...	18 Years - 75 Years	Rambam Health Care Campus

Spots Global Cancer Trial Database for their will be no intervention in any of the groups, the study is retrospective